ECP and solid organ transplantation.
Since its introduction in photomedicine in 1983 ECP (extracorporeal photopheresis) has over the past decades been established as a safe and effective treatment approach for the palliative management of patients with cutaneous T-cell lymphoma, the Sezary syndrome variant in particular. Subsequently its effectiveness has been well documented in a number of additional T-cell-mediated diseases, particularly in the treatment and prevention of acute and chronic graft-vs. -host disease. More recently, ECP has been successfully used to treat acute heart allograft rejection and chronic allograft dysfunction after lung transplantation without increasing infectious complications. As recently documented ECP was also used as a part of CNI (calcineurin inhibitors) sparing or staggering protocols. For this group of patients it is proposed that its efficacy may be partly attributed through direct induction of lymphocyte apoptosis (Tambur et al., 2000) [1] and subsequent production of regulatory T cells (Treg) (Lamioni et al., 2007) [2,3] without causing general immunosuppression. However, the exact indications for use of ECP within this framework are not yet finalized.
Department of Thoracic Surgery, Medical University of Vienna, Austria.
Peter
P
Jaksch
Department of Dermatology, Medical University of Vienna, Austria. Electronic address: robert.knobler@meduniwien.ac.at.
Robert
R
Knobler
D064591:Allografts; D006084:Graft Rejection / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D006086:Graft vs Host Disease / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D017893:Photopheresis / Q000379:methods*; D019737:Transplants
ECP; Extracorporeal photochemotherapy; Organ rejection; Organ transplantation